6,223 reports of this reaction
2.8% of all TACROLIMUS reports
#3 most reported adverse reaction
DRUG INTERACTION is the #3 most commonly reported adverse reaction for TACROLIMUS, manufactured by Astellas Pharma US, Inc.. There are 6,223 FDA adverse event reports linking TACROLIMUS to DRUG INTERACTION. This represents approximately 2.8% of all 222,557 adverse event reports for this drug.
TACROLIMUS has an overall safety score of 90 out of 100. Patients taking TACROLIMUS who experience drug interaction should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG INTERACTION is a less commonly reported adverse event for TACROLIMUS, but still significant enough to appear in the safety profile.
In addition to drug interaction, the following adverse reactions have been reported for TACROLIMUS:
The following drugs have also been linked to drug interaction in FDA adverse event reports:
DRUG INTERACTION has been reported as an adverse event in 6,223 FDA reports for TACROLIMUS. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG INTERACTION accounts for approximately 2.8% of all adverse event reports for TACROLIMUS, making it one of the most commonly reported side effect.
If you experience drug interaction while taking TACROLIMUS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.